XML 45 R36.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Operating Financial Results

The following table provides the operating financial results of our biopharmaceutical cancer therapeutics segment:

 

 

Three Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

June 30, 2026

 

 

 

 

 

 

 

 

 

 

 

 

Total Revenue

 

$

72,788

 

 

$

37,958

 

 

$

137,652

 

 

$

57,753

 

Less: Significant and other segment expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of product sales

 

 

3,208

 

 

 

1,279

 

 

 

5,841

 

 

 

2,164

 

Research and development expenses

 

 

 

 

 

 

 

 

 

 

 

 

Revumenib-related costs

 

 

35,493

 

 

 

28,155

 

 

 

61,218

 

 

 

48,960

 

Axatilimab-related costs

 

 

8,682

 

 

 

9,053

 

 

 

18,315

 

 

 

28,764

 

Other R&D programs

 

 

1,043

 

 

 

1,826

 

 

 

1,205

 

 

 

2,747

 

Personnel cost and other expenses

 

 

18,308

 

 

 

18,997

 

 

 

37,606

 

 

 

35,528

 

General and administrative expenses

 

 

 

 

 

 

 

 

 

 

 

 

Commercial-related expenses

 

 

9,869

 

 

 

9,914

 

 

 

17,590

 

 

 

20,739

 

Personnel cost and other expenses

 

 

16,298

 

 

 

19,307

 

 

 

32,999

 

 

 

38,389

 

Other SG&A expenses

 

 

5,868

 

 

 

4,993

 

 

 

11,008

 

 

 

9,405

 

Stock-based compensation

 

 

14,014

 

 

 

13,787

 

 

 

26,067

 

 

 

24,167

 

Royalty interest expense

 

 

12,119

 

 

 

7,854

 

 

 

23,965

 

 

 

15,903

 

Convertible note interest expense

 

 

555

 

 

 

—

 

 

 

555

 

 

 

—

 

Interest expense (income), net

 

 

(3,744

)

 

 

(5,946

)

 

 

(7,305

)

 

 

(13,127

)

Other expense, net

 

 

438

 

 

 

586

 

 

 

624

 

 

 

807

 

Segment net loss

 

$

(49,363

)

 

$

(71,847

)

 

$

(92,036

)

 

$

(156,693

)